Factor VIIa

This page contains recent news articles, when available, and an overview of Factor VIIa but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Annual Report to shareholders  -  Sep 11, 2008
...made progress in preclinical development of Increased demand for albumin in China, South America and a recombinant coagulation factor, Factor VIIa FP. Sydney Morning Herald,

Neose Technologies to Appeal NASDAQ Global Market Delisting ...  -  Aug 21, 2008
The lead candidates in its pipeline, GlycoPEG-GCSF for chemotherapy-induced neutropenia, and the GlycoPEGylated hemostasis compounds Factor VIIa, Business Wire (press release),

Vinculan al IOMA con los medicamentos truchos  -  Aug 20, 2008
Otro caso es el del medicamento Novoseven (Factor VIIA), para la hemofilia, detectado en la Obra Social de Industrias Químicas y Petroquímicas como Diario Hoy (Argentina),

Neose Technologies zugreifen - Global Biotech Investing  -  Aug 19, 2008
Novo Nordisk sei auf diesem ungefähr 1 Mrd. USD schweren Markt mit dem rekombinant Factor VIIa-Präparat Marktführer. Das Projekt mit Neose Technologies Stock World,

GTC Biotherapeutics Reports Second Quarter 2008 Financial Results  -  07 Aug 2008
...the collaboration programs in recombinant human coagulation factor VIIa, recombinant human alpha-1 antitrypsin, recombinant human coagulation factor IX, WELT ONLINE,

Bayer Buys Maxygen Hematology Drugs  -  Jul 10, 2008
Bayer is acquiring Maxygen’s hemophilia program, including a next-generation recombinant Factor VIIa protein, for $90 million upfront and a final potential FDA news (subscription),

Maxygen Reports Second Quarter 2008 Financial Results  -  Jul 31, 2008
MAXY-VII is a novel recombinant Factor VIIa protein created using Maxygen's MolecularBreeding(TM) directed evolution platform. Post-closing activities are MarketWatch

GTC Biotherapeutics Receives NASDAQ Notice of Non-Compliance  -  Jul 18, 2008
These proteins include recombinant forms of human coagulation factor VIIa, factor VIII, factor IX, and alpha-1 antitrypsin. GTC also has a monoclonal MarketWatch

Neose Technologies Announces GlycoPEG-GCSF Abstract Accepted for ...  -  Jul 28, 2008
The lead candidates in its pipeline, GlycoPEG-GCSF for chemotherapy-induced neutropenia, and the GlycoPEGylated hemostasis compounds Factor VIIa, Business Wire (press release),

Haemophilia and inhibitors 2: surgical management  -  Jul 8, 2008
The advent of bypassing therapies – such as factor VIII inhibitor bypassing fraction and recombinant factor VIIa (rFVIIa) – has made surgery possible for Nursing Times,

Neose to Host Second Quarter 2008 Conference Call  -  Jul 31, 2008
The lead candidates in its pipeline, GlycoPEG-GCSF for chemotherapy-induced neutropenia, and the GlycoPEGylated hemostasis compounds Factor VIIa, Genetic Engineering News (press release),

바�?�엘, 막시젠 혈우병 치료약물 기술등 �?�수  -  Jul 13, 2008
MAXY-VII는 Factor VIIa 단백 선�?�치료 후보 물질로 3/4분기�? 제1임�? 실험�? 진입�?� 것으로 기대하고 있다. 혈우병 환�?�?� 약 20-30%가 현재 치료제로 항체가 발�? 메디�?�뉴스,

Maxygen selling hemophilia unit to Bayer  -  03 Jul 2008
Roughly 20 percent to 30 percent of patients with hemophilia develop antibodies to current therapies, so a mechanism called Factor VIIa is used to help CNNMoney.com

2008-07-02 16:17:18 - www.companiesandmarkets.com adds new report ...  -  03 Jul 2008
In addition to ATryn, GTC is working with LFB Biotechnologies to develop recombinant forms of human factor VIIa and a CD20 monoclonal antibody. PR-Inside.com (Pressemitteilung),

Unusual 11 Mid-Day Movers 7/2: MAXY, APOL, ERII, NSTR Higher; MBRK ...  -  03 Jul 2008
...today announced the acquisition of Maxygen's hemophilia program assets, including a next-generation recombinant Factor VIIa protein known as MAXY-VII. StreetInsider.com (subscription),

BUYINS.NET: MXWL, PCYC, PFCB, PSEC, PVTB, SYBT Have Also Been ...  -  03 Jul 2008
PCI-24783, a preclinical stage small molecule inhibitor of Factor VIIa for cancer therapy; and PCI-32765, a preclinical stage small molecule tyrosine Trading Markets (press release),

MAXY: Announce Agreement with Bayer  -  03 Jul 2008
...the acquisition of Maxygen's (NASDAQ:MAXY) hemophilia program assets, including a next-generation recombinant Factor VIIa protein known as MAXY-VII. Trading Markets (press release),

Stock of biopharma company rockets on Bayer deal  -  03 Jul 2008
Bayer has agreed to purchase Maxygen’s “hemophilia program assets, including a next-generation recombinant Factor VIIa protein known as MAXY-VII. Stockhouse,

OTCPicks.com Daily Market Movers Digest Midday Report for ...  -  03 Jul 2008
...a granulocyte colony stimulating factor that is in Phase IIa clinical trial for the treatment of neutropenia; MAXY-VII, a factor VIIa product that is in Emailwire

Maxygen Receives Approval for Clinical Trial of Factor VIIa in the ...  -  Jun 11, 2008
MAXY-VII is the company’s next-generation Factor VIIa protein for the treatment of hemophilia. Patient dosing is on schedule to begin in the second half of WELT ONLINE,

Maxygen granted approval for Factor VIIa trial in UK  -  Jun 12, 2008
Maxy-VII is the company's next-generation Factor VIIa protein for the treatment of hemophilia. Patient dosing is on schedule to begin in the second half of Trading Markets (press release),

Pharmaceutical Study: Less Hemorrhaging After Stroke, But Not ...  -  Jun 16, 2008
16, 2008) — An international study published in May 2008 in the New England Journal of Medicine has shown that the coagulation factor VIIa can limit the Science Daily (press release)

Hemophilia - Extended Half-Life Recombinant VIIa Leads To Longer ...  -  Jun 4, 2008
CSL Behring presented results of a pre-clinical study that not only demonstrates the feasibility of genetically fusing factor VIIa to human albumin, Medical News Today (press release),

Novo Nordisk And Neose Announce Completion Of Initial Phase 1 ...  -  Jun 5, 2008
Recombinant Factor VIIa is used in the treatment of bleeding episodes and for the prevention of bleeding during surgery or invasive procedures in patients Medical News Today (press release),

BioGeneriX and Neose Technologies Initiate Phase 2 Trial for ...  -  Jun 23, 2008
The lead candidates in its pipeline, GlycoPEG-GCSF for chemotherapy-induced neutropenia, and the GlycoPEGylated hemostasis compounds Factor VIIa, Business Wire (press release),

BioGeneriX And Neose Technologies Initiate Phase 2 Trial For ...  -  Jun 25, 2008
The lead candidates in its pipeline, GlycoPEG-GCSF for chemotherapy-induced neutropenia, and the GlycoPEGylated hemostasis compounds Factor VIIa, Medical News Today (press release),

Novo Nordisk Halts Trial of Traumatic Bleeding Drug for Futility  -  Jun 18, 2008
NovoSeven (coagulation factor VIIa [recombinant]) is a hemophilia drug that was undergoing a safety and efficacy study in severely injured blunt trauma FDA news (subscription),

Market Report -- In Play (MAXY)  -  Jul 2, 2008
...hematology agreement Bayer HealthCare wil acquire Maxygen's hemophilia program assets, including a recombinant Factor VIIa protein known as MAXY-VII. MSN Money

Maxygen to Present at the Goldman Sachs 29th Annual Global ...  -  Jun 3, 2008
Also in Maxygen’s pipeline is a new Factor VIIa product candidate for the treatment of hemophilia and new CTLA4-Ig product candidates for the treatment of Business Wire (press release),

OTCPicks.com: OTCPicks.com Stocks to Watch for Friday, June 6th ...  -  Jun 6, 2008
PCI-24783, a preclinical stage small molecule inhibitor of Factor VIIa for cancer therapy; and PCI-32765, a preclinical stage small molecule tyrosine Insurance News Net (press release),

BUYINS.NET: BTC, GNB, GFG, ZLC, EMMS, PCYC Have Been Added To ...  -  Jun 17, 2008
PCI-24783, a preclinical stage small molecule inhibitor of Factor VIIa for cancer therapy; and PCI-32765, a preclinical stage small molecule tyrosine Trading Markets (press release),

OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday ...  -  Jun 5, 2008
PCI-24783, a preclinical stage small molecule inhibitor of Factor VIIa for cancer therapy; and PCI-32765, a preclinical stage small molecule tyrosine Trading Markets (press release),

OTCPicks.com Stocks to Watch for Friday, June 6th TRCA, PCYC, SRSR  -  Jun 5, 2008
PCI-24783, a preclinical stage small molecule inhibitor of Factor VIIa for cancer therapy; and PCI-32765, a preclinical stage small molecule tyrosine Emailwire

BAC to develop Factor VIIa purification ligand for LFB  -  02 Jun 2008
The new project, financial terms of which have not been disclosed, will seek to develop a ligand that has high-affinity for Factor VIIa-specific for In-PharmaTechnologist.com,

Novo Nordisk and Neose Announce Completion of Initial Phase 1 ...  -  02 Jun 2008
Recombinant Factor VIIa is used in the treatment of bleeding episodes and for the prevention of bleeding during surgery or invasive procedures in patients Business Wire (press release),

Cost effectiveness of recombinant factor VIIa for treatment of ...  -  May 19, 2008
Phase I/II placebo-controlled clinical trials of recombinant Factor VIIa (rFVIIa) suggested that administration of rFVIIa within 4 hours after onset of 7thSpace Interactive (press release),

FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor ...  -  May 13, 2008
By Novo Nordisk Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved NovoSeven(R) RT (Coagulation Factor VIIa SunHerald.com,

Catalyst Biosciences Selects Drug Development Candidate in Factor ...  -  May 6, 2008
..."Patients receiving factor VIIa therapy typically require multiple doses of drug and extended treatment times to manage acute bleeding episodes," said Earthtimes (press release),

Custom ligand for purifying recombinant  -  May 29, 2008
LFB and GTC are producing Factor VIIa in the milk of animals that express this recombinant protein during lactation. BAC has a proven reputation for the Laboratory Talk,

US clears new version of Novo Nordisk clot therapy  -  May 9, 2008
NovoSeven RT is a genetically engineered version of Factor VIIa, a protein found in plasma that is essential for the clotting of blood. Reuters

FDA Approves New Formulation of Coagulation Therapy  -  May 12, 2008
The US Food and Drug Administration today approved a new formulation of the genetically engineered version of Factor VIIa, a plasma protein essential for Media Newswire (press release),

Neose Technologies receives payment from Novo Nordisk to develop ...  -  May 19, 2008
...versions of recombinant Factors VIIa and VIII. A Phase I trial of GlycoPEG-Factor VIIa is currently ongoing, Neose noted. by RTT Staff Writer. RTT News,

FDA Approvals: Amitiza, Strattera, NovoSeven RT  -  May 15, 2008
Describe the potential benefits of a new formulation for recombinant coagulation factor VIIa intravenous injection. Disclosure: Yael Waknine has disclosed Medscape (subscription)

LFB Biotechnologies and GTC Biotherapeutics to Collaborate on ...  -  May 8, 2008
In addition to the recombinant alpha-1 antitrypsin program, the GTC/LFB Biotechnologies collaboration includes recombinant factor VIIa, recombinant factor Business Wire (press release),

Maxygen Inc (NASDAQ:MAXY) to Present at Rodman & Renshaw Annual ...  -  May 12, 2008
...a granulocyte colony stimulating factor (G-CSF) for the treatment of neutropenia; MAXY-VII, a factor VIIa product for the treatment of hemophilia and TransWorldNews (press release),

NovoSeven RT approved to control surgical bleeding  -  May 12, 2008
The FDA has approved Novo Nordisk's NovoSeven RT (recombinant human coagulation factor VIIa), another formulation of NovoSeven, that can be stored at room Prescribing Reference,

Neose Technologies Reports First Quarter Financial Results  -  May 8, 2008
The lead candidates in its pipeline, GlycoPEG-GCSF for chemotherapy-induced neutropenia, and the GlycoPEGylated hemostasis compounds Factor VIIa, WELT ONLINE,

Other News To Note  -  May 6, 2008
CB813 has demonstrated a significant improvement in potency compared with the marketed recombinant factor VIIa product, NovoSeven and a competing, TMCnet

Commercial Solutions Q2 Revenues Down 17.4  -  May 6, 2008
Revenue decreased due primarily to loss of revenues from a Roche collaboration agreement to develop a novel Factor VIIa for trauma indications. RTT News,

Rodman & Renshaw Global Healthcare Conference 2008 Presenter Profiles  -  May 16, 2008
Also in Maxygen's pipeline is a new Factor VIIa product candidate for the treatment of hemophilia and new CTLA4-Ig product candidates for the treatment of Centre Daily Times,

Maxygen First Quarter 2008 Financial Results Conference Call Notice  -  23 Apr 2008
Also in Maxygen’s pipeline is a new Factor VIIa product candidate for the treatment of hemophilia and new CTLA4-Ig product candidates for the treatment of Business Wire (press release),

Pharmacyclics' Novel Factor VIIa Inhibitor Demonstrates Potential ...  -  Apr 16, 2008
..."These findings indicate that Factor VIIa inhibition is potentially a novel treatment approach for patients whose tumors depend on Factor VIIa activity for CNNMoney.com (press release)

Too Much Of A Good Thing: High Levels Of Factor VIIa Cause ...  -  Apr 10, 2008
Individuals with hemophilia lack either factor VIII or factor IX, proteins crucial for the cascade of events that leads to blood clotting. Medical News Today (press release),

Novozymes licenses albumin technology to CSL Behring  -  Apr 2, 2008
This proof-of-principle study showed for the first time that it was possible to fuse the coagulant Factor VIIa (FVIIa) genetically to human albumin, In-PharmaTechnologist.com,

Novozymes Grants CSL Behring an Exclusive License to its Albumin ...  -  Mar 31, 2008
Pre-clinical data presented at the American Society of Hematology 49th Annual Meeting and Exposition suggests that fusion of Factor VIIa (FVIIa) to PharmaLive.com (press release),

Pharmacyclics Announces Multiple Presentations at the American ...  -  Apr 3, 2008
..."In addition to data on our HDAC inhibitor, other presentations describe our Factor VIIa and Btk inhibitors, which we anticipate will enter clinical testing FOXBusiness

AACR Roundup  -  Apr 16, 2008
Pharmacyclics Inc., of of Sunnyvale, Calif, presented preclinical results demonstrating the antitumor activity of PCI-27483, its small-molecule Factor VIIa TMCnet

BUYINS.NET: DMC, ANSW, BCRX, CBMX, CHINA, CHRT Have Also Been ...  -  Apr 3, 2008
Tissue Factor/Factor VIIa, a product under lead optimization stage, is intended for the treatment of acute coronary syndromes and complications associated Trading Markets (press release),

Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine ...  -  Mar 31, 2008
Also in Maxygen's pipeline are a new Factor VIIa product candidate for the treatment of hemophilia and new CTLA4-Ig product candidates for the treatment of FOXBusiness

Neose Technologies Reports Fourth Quarter and Year End 2007 ...  -  11 Mar 2008
The lead candidates in its pipeline, GlycoPEG-GCSF for chemotherapy-induced neutropenia, and the GlycoPEGylated hemostasis compounds Factor VIIa, Centre Daily Times,

Pharmacyclics to cut 40% of staff Silicon Valley / San Jose ...  -  Feb 28, 2008
...trials and our Btk and Factor VIIa inhibitor compounds expected to enter the clinic in the third quarter of this year," said CEO Dr. Richard A. Miller. Bizjournals.com,

GTC Biotherapeutics Reports Fourth Quarter and Year End 2007 ...  -  Mar 6, 2008
We developed production animals for the recombinant human coagulation factor VIIa program with LFB Biotechnologies. We licensed exclusive rights to North Business Wire (press release),

Maxygen to Present at the Roth 20th Annual OC Growth Stock Conference  -  Feb 12, 2008
Also in Maxygen's pipeline is a new Factor VIIa product candidate for the treatment of hemophilia and new CTLA4-Ig product candidates for the treatment of FOXBusiness

Maxygen Inc. Q4 2007 Earnings Call Transcript  -  Feb 12, 2008
Many hemophilia patients are underserved by the current Factor VIIa drug on the market, and we believe MAXY-VII may better serve this patient population. Seeking Alpha,

Pharmacyclics Cuts Staff, Shifts Focus to Early Stage Candidates  -  Feb 29, 2008
A second preclinical candidate, PCI-27483, is a small-molecule inhibitor of Factor VIIa, which is associated with blood clotting, angiogenesis and tumor BioWorld Online,

Intensive Care of Patients with Acute Liver Failure  -  Feb 29, 2008
In select patients requiring invasive procedures, administration of recombinant factor VIIa may be useful. 3 The authors recognized that placement of an AAP Grand Rounds (subscription),

GTC Biotherapeutics, Racing Against Time to Prove the Worth of ...  -  Feb 11, 2008
GTC also plans to produce a protein called factor VIIa, used to treat hemophilia. Currently extracted …Next Page » Xconomy,

:

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.